npj Parkinson s Disease · 2025 · 18 citations · 38 references
Life SciencesClinical SciencesNeuroscienceMolecular PathologyNeurobiology Of DiseaseNeurodegenerationBiomarker DiscoveryBiomarkers Of NeurodegenerationDisease PhenotypingNeurodegenerative DiseasesNeurodegenerative DisordersParkinson DiseaseBiomarker-based PrognosticationBiomarkers Of Parkinsonian DisordersBlood-based BiomarkersDisability PredictionLongitudinal Cohort AnalysisParkinson Disease BiomarkersPredictors Of Disease ProgressionPrognostic Biomarker Discovery
In a prospective longitudinal study with 218 Parkinson's disease (PD) patients in the discovery cohort and 84 in the validation cohort, we aimed to identify novel blood biomarkers predicting disability milestones in PD. Through Least Absolute Shrinkage and Selection Operator-Cox (Lasso-Cox) regression, developed nomogram predictive model and Linear mixed-effects models, we identified low level of plasma fibronectin (pFN) as one of the best-performing risk markers in predicting disability milestones. A low level of pFN was associated with a short milestone-free survival period in PD. Longitudinal analysis showed an annual decline in the rate of pFN was significantly associated with the annual elevation rate in the Hoehn-Yahr stage. Moreover, pFN level was negatively correlated with phosphorylated α-synuclein, and a low level of pFN was associated with BBB disruption in the striatum on neuroimaging, providing evidence for pFN's role in PD progression. We finally identified pFN as a novel blood biomarker that predicted first-milestone disability in PD.
38
The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
M. A. Hely, Wayne G.J. Reid, Michael Adena et al. · Movement Disorders · 2008 · 2.2K citations · Full text
Medicine, Neurology, Neuroscience +12
Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction
Daniel A. Nation, Melanie D. Sweeney, Axel Montagne et al. · Nature Medicine · 2019 · 1.7K citations